Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03263299
Other study ID # 8
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received August 24, 2017
Last updated August 24, 2017
Start date August 2017
Est. completion date September 2018

Study information

Verified date August 2017
Source Cairo University
Contact Ahmed Maged, MD
Phone 01005227404
Email prof.ahmedmaged@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ovarian stimulation will be done using the Microdose flare-up regimen. The patient will receive diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation will be initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) will be injected when at least 2 follicles 18 mm were observed on ultrasonography.

Oocytes willbe retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding.

After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization.

The luteal phase support will be initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done.


Description:

Ovarian stimulation was done using the Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) were injected when at least 2 follicles 18 mm were observed on ultrasonography.

Oocytes were retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding.

After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization.

The luteal phase support was initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done.

Serum β-hCG was performed 14 days after the embryo transfer to confirm chemical pregnancy. Clinical pregnancy was confirmed when there was an evidence of gestational sac, embryo and fetal heart activity at time of transvaginal ultrasound evaluation by the 6th week.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date September 2018
Est. primary completion date August 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 39 Years
Eligibility Inclusion Criteria:

1. Patients with a history of one or more failed IVF cycles with three or less retrieved oocytes

2. No age limitation

3. Patients with an inadequate ovarian response in previous cycle

4. Low estradiol (E2) levels in response to ovarian stimulation in previous cycle

5. Lower number of retrieved oocytes in previous trials.

Exclusion Criteria:

1. Severe male factor (azospermia)

2. Hydrosalpinx

3. History of endometriosis

4. Endocrine or metabolic disorders

5. Follicle stimulating hormone (FSH) level > 15 mIU.

6. Antimullerian hormone (AMH)< 0.5 ng/ml

7. Any uterine causes of infertility e.g. septate uterus

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cabergoline
Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
Aspirin
Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
GnRH agonist
Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Locations

Country Name City State
Egypt Kasr Alainy medical school Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical pregnancy Intrauterine gestational sac detection by transvaginal ultrasound 4 weeks after embryo transfer
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03684824 - Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment N/A
Not yet recruiting NCT03683043 - Comparative Study Between ICSI Results in Transvaginal Ultrasound Guided Embryo Transfer and Transabdominal Ultrasound Guided Embryo Transfer Phase 4
Recruiting NCT02329197 - Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure Phase 4
Completed NCT02764255 - Embryoscope and Reproductive Outcome N/A
Recruiting NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF N/A
Completed NCT02674178 - FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women Phase 4
Completed NCT01576991 - Telomeres and Reproduction in Women N/A
Recruiting NCT03457233 - The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles N/A
Completed NCT02660125 - Endometrial Injury and Implantation Rates Before First ICSI Cycle N/A
Completed NCT03402620 - Poor Responders Infertile Patients -A Great Clinical Challenge N/A
Completed NCT03831542 - Effect of Follicular Flushing in Patients With Mono-follicular Growth Undergoing In Vitro Fertilization
Completed NCT03118830 - Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Phase 4
Recruiting NCT02383394 - Factors Associated With Pregnancy Loss in IVF Women N/A